Keywords: bb, moves, ra, compound, into, development, british
BB moves RA compound into development
Article | 14 October 1999
British Biotech has moved its rheumatoid arthritis investigationalcompound BB-2827 into clinical development. BB-2827 is a collagenase-selective matrix metalloproteinase inhibitor which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
